We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $11.5B
1-Year Est. Return 168.77%
This Fund
S&P 500
This Quarter Est. Return
-2.38%
1 Year Est. Return
+168.77%
3 Year Est. Return
+596.08%
5 Year Est. Return
+846.46%
10 Year Est. Return
+54,223.74%
AUM
$1.86B
AUM Growth
-$456M
Cap. Flow
-$272M
Cap. Flow %
-14.61%
Top 10 Hldgs %
79.17%
Holding
33
New
4
Increased
4
Reduced
3
Closed
8

Top Buys

Rank Stock Value
1
ZGNX
Zogenix, Inc.
ZGNX
+$54M
2
MYOV
Myovant Sciences Ltd.
MYOV
+$44.8M
3
PRVL
Prevail Therapeutics Inc. Common Stock
PRVL
+$40M
4
STOK icon
Stoke Therapeutics
STOK
+$30.1M
5
XFOR icon
X4 Pharmaceuticals
XFOR
+$14.6M

Top Sells

Rank Stock Value
1
IFRX icon
InflaRx
IFRX
+$106M
2
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$70.5M
3
SAGE
Sage Therapeutics
SAGE
+$61.1M
4
KALV
KalVista Pharmaceuticals
KALV
+$41.2M
5
AXSM icon
Axsome Therapeutics
AXSM
+$39.1M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BCRX icon
26
BioCryst Pharmaceuticals
BCRX
$2.09B
– –
-8,659,983
Closed -$70.5M
IFRX icon
27
InflaRx
IFRX
$298M
– –
-2,810,708
Closed -$106M
IOVA icon
28
Iovance Biotherapeutics
IOVA
$4.24B
– –
-2,610,510
Closed -$24.8M
KALV
29
DELISTED
KalVista Pharmaceuticals
KALV
– –
-1,441,070
Closed -$41.2M
MRNA icon
30
Moderna
MRNA
$57.4B
– –
-1,513,929
Closed -$30.8M
SAGE
31
DELISTED
Sage Therapeutics
SAGE
– –
-384,001
Closed -$61.1M
EIGR
32
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
– –
-80,515
Closed -$33.8M
MNTA
33
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
– –
-2,563,657
Closed -$37.3M
1
2

Similar funds

AAIS
ABN AMRO Investment Solutions Paris Cedex 008 $11.5B AUM 32.2% 1-Year Est. Return
MG
Mather Group Chicago, Illinois $11.5B AUM 18.82% 1-Year Est. Return
CC
Centiva Capital New York $11.5B AUM 31.97% 1-Year Est. Return
AI
Axiom Investors Greenwich, Connecticut $11.6B AUM 69.67% 1-Year Est. Return
BMSSC
B. Metzler seel. Sohn & Co Frankfurt, Germany $11.6B AUM 34.29% 1-Year Est. Return
HTC
Haverford Trust Company Radnor, Pennsylvania $11.6B AUM 18.97% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

RA Capital Management's Q2 2019 Portfolio in Review

As of Q2 2019, RA Capital Management held 33 positions worth $1.86B, down 20% from $2.32B the previous quarter. Its ten largest holdings account for 79% of the portfolio.

RA Capital Management withdrew a net $272M in Q2 2019, closing 8 positions and reducing 3 holdings. Its most notable exit was InflaRx, an estimated $106M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, RA Capital Management opened a new position in Prevail Therapeutics Inc. Common Stock worth $36.2M.

  • RA Capital Management's largest Q2 2019 buy was Prevail Therapeutics Inc. Common Stock: 2,743,625 shares worth $36.2M.
  • RA Capital Management added most to Zogenix, Inc. in Q2 2019, an estimated $54M increase.
  • RA Capital Management's biggest Q2 2019 reduction was Axsome Therapeutics, cutting an estimated $39.1M.
  • RA Capital Management fully exited InflaRx in Q2 2019, selling an estimated $106M.
  • RA Capital Management's ten largest holdings make up 79% of its $1.86B portfolio in Q2 2019.
  • RA Capital Management opened 4 new positions and closed 8 in Q2 2019.
  • RA Capital Management's portfolio value fell 20% quarter-over-quarter to $1.86B.

Based on RA Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.